Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs)

Introduction: Immune checkpoint inhibitors (ICIs) are now standard of care in many cancers. They can generate immune-related adverse events (irAEs), but no biomarkers are available to identify patients who are more likely to develop irAEs. We assess the association between pre-existing autoantibodie...

Full description

Saved in:

Bibliographic Details
Main Authors:	A Daban, C Gonnin, L Phan, A Saldmann, C Granier, A Lillo-Lelouet, C Le Beller, J Pouchot, l Weiss, E Tartour, E Fabre, J Medioni, S Oudard, YA Vano, MA Dragon-Durey, A. Simonaggio
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2023-12-01
Series:	OncoImmunology
Subjects:	Immune checkpoint inhibitors immune-related adverse events pre-existing antibodies
Online Access:	https://www.tandfonline.com/doi/10.1080/2162402X.2023.2204754
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs)

Similar Items